Biological drugs face challenges in their uptake into the national health services, as they are often not used in treatment regimes despite being the best option for patients. Biologics pose a high initial investment to the administration however, they also provide advantages in economic efficiency in the long run.
For this reason, experts propose that biologics should be measured through other variables in order to evaluate their cost-effectiveness, such as life years gained, diseases prevented, symptoms relieved and improved quality of life in patients.
Biological drugs are now estimated to account for 33 percent of approved drugs . Its expenditure is around 40 percent of the average hospital pharmacy expenditure in Spain, generating about 3 billion annually.